Markets:

Overview

News

Currencies

International

Treasuries

C4 Therapeutics, Inc. - Common Stock (NQ:CCCC)

2.220 -0.110 (-4.72%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 15, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about C4 Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

US Stocks Edge Lower; Inflation Rate Slows to 3.1% In November ↗

December 12, 2023

U.S. stocks traded slightly lower this morning, following the release of inflation data on Tuesday. Following the market opening Tuesday, the Dow traded down 0.04% to 36,389.01 while the NASDAQ fell...

Via Benzinga

Topics Economy Stocks

Why Is Cancer-Focused C4 Therapeutics Stock Soaring Today? ↗

December 12, 2023

C4 Therapeutics Inc (NASDAQ: CCCC) has entered into an exclusive license and collaboration agreement with Merck & Co Inc (NYSE: MRK) to develop degrader-antibody conjugates (DACs), an emerging modality...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

December 12, 2023

Via Benzinga

C4 Therapeutics Announces License and Research Collaboration with Merck to Discover and Develop Degrader-Antibody Conjugates (DACs)

December 12, 2023

Initial Focus on One Oncology Target, Exclusive to Collaboration; Merck has Option for Three Additional Targets

From C4 Therapeutics, Inc.

Via GlobeNewswire

Expert Ratings for C4 Therapeutics ↗

November 03, 2023

Via Benzinga

C4 Therapeutics Inc. (NASDAQ: CCCC) Highlighted for Surprising Price Action

May 30, 2023

Via Investor Brand Network

C4 Therapeutics to Host Webcast to Present New Dose Escalation Data from CFT7455 Phase 1 Study in Relapsed/Refractory Multiple Myeloma

November 28, 2023

From C4 Therapeutics, Inc.

Via GlobeNewswire

C4 Therapeutics Strengthens Board of Directors with Owen Hughes Appointment

November 20, 2023

Owen Hughes, Accomplished Life Sciences Executive with Deep Experience Across Investing, Operations and Governance, Appointed as Independent Member of the Board of Directors

From C4 Therapeutics, Inc.

Via GlobeNewswire

C4 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

November 01, 2023

From C4 Therapeutics, Inc.

Via GlobeNewswire

The Latest Analyst Ratings for C4 Therapeutics ↗

May 30, 2023

Via Benzinga

Looking Into C4 Therapeutics's Return On Capital Employed ↗

May 18, 2023

Via Benzinga

Why EngageSmart Shares Are Trading Higher By Around 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

October 23, 2023

Gainers INVO Bioscience, Inc. (NASDAQ: INVO) jumped 375% to $2.57 as the company agreed to acquire NAYA Biosciences in an all-stock transaction.

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

October 23, 2023

Via Benzinga

C4 Therapeutics Announces Upcoming Data Presentations for CFT8634, an Orally Bioavailable BiDAC™ Degrader in Development for Synovial Sarcoma and SMARCB1-Null Tumors, and CFT7455, an Orally Bioavailable MonoDAC™ Degrader in Development for Multiple

October 11, 2023

From C4 Therapeutics, Inc.

Via GlobeNewswire

C4 Therapeutics Announces Chief Financial Officer Succession

September 05, 2023

From C4 Therapeutics, Inc.

Via GlobeNewswire

C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

August 08, 2023

From C4 Therapeutics, Inc.

Via GlobeNewswire

C4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 17, 2023

From C4 Therapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

July 06, 2023

Via Benzinga

Nasdaq Edges Lower Following Fed Minutes; C4 Therapeutics Shares Jump ↗

July 05, 2023

U.S. stocks traded mostly lower toward the end of trading, with the Dow Jones dropping around 100 points on Wednesday. The Dow traded down 0.30% to 34,316.70 while the NASDAQ fell 0.04% to 13,811.43....

Via Benzinga

Crude Oil Rises Sharply; Impel Pharmaceuticals Shares Spike Higher ↗

July 05, 2023

U.S. stocks traded lower midway through trading, with the Dow Jones dropping over 50 points on Wednesday. The Dow traded down 0.17% to 34,361.31 while the NASDAQ fell 0.14% to 13,797.72. The S&P 500,...

Via Benzinga

C4 Therapeutics Inc. (NASDAQ: CCCC) is One of Wednesday Morning’s Most Active Stocks

July 05, 2023

Via Investor Brand Network

Dow Drops 150 Points; US Factory Orders Increase 0.3% In May ↗

July 05, 2023

U.S. stocks traded lower this morning, with the Dow Jones dropping over 150 points on Wednesday. Following the market opening Wednesday, the Dow traded down 0.46% to 34,259.45 while the NASDAQ fell...

Via Benzinga

Why 1847 Holdings Shares Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

July 05, 2023

Gainers Allarity Therapeutics, Inc. (NASDAQ: ALLR) shares surged 87% to $11.78 after the company said the initial data from Phase 2 trial of Ixempra shows potential for improved clinical benefit in...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

July 05, 2023

Via Benzinga

C4 Therapeutics Stock Is Surging: What's Going On? ↗

July 05, 2023

C4 Therapeutics Inc (NASDAQ: CCCC) shares are rising Wednesday after the clinical-stage biopharmaceutical company announced the FDA cleared its investigational new drug (IND)

Via Benzinga

C4 Therapeutics Announces FDA Clearance of Investigational New Drug Application for CFT8919, an Orally Bioavailable BiDAC™ Degrader Targeting EGFR L858R for Non-Small Cell Lung Cancer

July 05, 2023

From C4 Therapeutics, Inc.

Via GlobeNewswire

C4 Therapeutics Appoints Leonard Reyno, M.D., as Chief Medical Officer

June 20, 2023

From C4 Therapeutics, Inc.

Via GlobeNewswire

Week In Review: Betta Pharma Enters $392 Million Deal For C4 Therapeutics’ NSCLC Drug ↗

June 03, 2023

Hangzhou Betta Pharma acquired greater China rights for a novel non-small cell lung cancer drug from Boston’s C4 Therapeutics in a deal worth up to $392 million. Additionally, Lynk Pharma of Hangzhou...

Via Talk Markets

The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree ↗

June 02, 2023

Big Pharma is facing a patent cliff that could siphon off billions in revenue.

Via Investor's Business Daily

C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDAC™ Degrader of EGFR L858R for NSCLC

May 30, 2023

From C4 Therapeutics, Inc.

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.